The detection of preclinical Parkinson's disease: What is the role of positron emission tomography?
Article first published online: 12 OCT 2004
Copyright © 1993 Movement Disorder Society
Volume 8, Issue 3, pages 271–277, 1993
How to Cite
Sawle, G. V. (1993), The detection of preclinical Parkinson's disease: What is the role of positron emission tomography?. Mov. Disord., 8: 271–277. doi: 10.1002/mds.870080304
- Issue published online: 12 OCT 2004
- Article first published online: 12 OCT 2004
- Positron emission tomography;
- Parkinson's disease;
On clinical criteria alone, the diagnosis of early Parkinson's disease can be difficult and, by definition, the prospective recognition of preclinical Parkinson's disease is impossible. Positron emission tomography (PET) using [18F]dopa as tracer has been proposed as a means of identifying patients with preclinical disease. The number of subjects detected to date has been few; most have been identified by serendipity or during the course of family studies. This review examines the significance of a single abnormal scan in an apparently healthty subject in terms of the relationship between normal and abnormal values and the time course of the disease.